Project
Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial
Aborted ยท 2019 until 2021
Neuwirth Christoph
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Aborted
Start Date
2019
End Date
2021
Financing
Industry
Brief description/objective
A multicenter, non-randomized, open label trial, to assess long term safety and efficacy of Arimoclomol in subjects with Amyotrophic Lateral Sclerosis (ALS)who have completed the ORARIALS-01 trial.